CA1310269C - Utilisation d'inhibiteurs de la reductase de l'aldose pour accroitre la sensibilite a l'insuline dans le diabete sucre - Google Patents

Utilisation d'inhibiteurs de la reductase de l'aldose pour accroitre la sensibilite a l'insuline dans le diabete sucre

Info

Publication number
CA1310269C
CA1310269C CA000561908A CA561908A CA1310269C CA 1310269 C CA1310269 C CA 1310269C CA 000561908 A CA000561908 A CA 000561908A CA 561908 A CA561908 A CA 561908A CA 1310269 C CA1310269 C CA 1310269C
Authority
CA
Canada
Prior art keywords
insulin
diabetes mellitus
spiro
diones
aldose reductase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA000561908A
Other languages
English (en)
Inventor
Billie M. York, Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcan Laboratories Inc
Original Assignee
Alcan Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcan Laboratories Inc filed Critical Alcan Laboratories Inc
Application granted granted Critical
Publication of CA1310269C publication Critical patent/CA1310269C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA000561908A 1987-03-20 1988-03-18 Utilisation d'inhibiteurs de la reductase de l'aldose pour accroitre la sensibilite a l'insuline dans le diabete sucre Expired - Fee Related CA1310269C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2851287A 1987-03-20 1987-03-20
US028,512 1987-03-20

Publications (1)

Publication Number Publication Date
CA1310269C true CA1310269C (fr) 1992-11-17

Family

ID=21843865

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000561908A Expired - Fee Related CA1310269C (fr) 1987-03-20 1988-03-18 Utilisation d'inhibiteurs de la reductase de l'aldose pour accroitre la sensibilite a l'insuline dans le diabete sucre

Country Status (6)

Country Link
EP (1) EP0306525A4 (fr)
JP (1) JPH01503460A (fr)
KR (1) KR890700346A (fr)
AU (1) AU598366B2 (fr)
CA (1) CA1310269C (fr)
WO (1) WO1988006887A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
KR100343944B1 (ko) * 2001-02-14 2002-07-24 주식회사 에이.비.아이 L-2-옥소씨아졸리딘-4-카르복실산 또는 그 염을 유효성분으로 함유하는 당뇨병 치료제 조성물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130714A (en) * 1977-05-23 1978-12-19 Pfizer Inc. Hydantoin therapeutic agents
US4147797A (en) * 1978-08-11 1979-04-03 Pfizer Inc. Spiro-furanohydantoin derivatives
US4251258A (en) * 1978-09-29 1981-02-17 Monsanto Company N-(Substituted carbonyl) derivatives of N-phosphinylmethylglycinates and the herbicidal use thereof
US4226875A (en) * 1979-04-02 1980-10-07 Pfizer Inc. Novel spiro-oxazolidinediones
US4235911A (en) * 1979-06-13 1980-11-25 Pfizer Inc. Hydantoin derivatives
US4254108A (en) * 1979-11-08 1981-03-03 Ayerst, Mckenna & Harrison Inc. Thioxo-1H-benz[de]isoquinoline-2(3H)-acetic acid derivatives and antidiabetic use thereof
US4438272A (en) * 1982-04-15 1984-03-20 Alcon Laboratories, Inc. Spiro-(fluoren-9,4'-imidazolidine)-2',5'-diones
US4436745A (en) * 1982-04-15 1984-03-13 Alcon Laboratories, Inc. Method of inhibiting aldose reductase activity
US4430337A (en) * 1982-06-23 1984-02-07 Pfizer Inc. Alicyclic substituted oxazolidine-2,4-diones having hypoglycemic activity
US4864028A (en) * 1983-09-14 1989-09-05 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives
US4537892A (en) * 1983-09-14 1985-08-27 Alcon Laboratories, Inc. Spiro-tricyclicaromatic succinimide derivatives as inhibitors of aldose reductase
US4600717A (en) * 1984-04-11 1986-07-15 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in ophthalmic wound healing
US4609663A (en) * 1984-09-11 1986-09-02 Alcon Laboratories, Inc. Aldose reductase inhibitors useful in glaucoma therapy
JPS6178725A (ja) * 1984-09-20 1986-04-22 アメリカン・ホーム・プロダクツ・コーポレイシヨン 安定化されたトルレスタート回転異性体組成物
US4604406A (en) * 1984-11-16 1986-08-05 Ayerst, Mckenna & Harrison, Inc. N-[6-methoxy-5-(perfluoroalkyl)-1-naphtholyl]-N-methylglycines and their thionaphthoyl analogs
US4575507A (en) * 1985-05-29 1986-03-11 Pfizer Inc. Spiro-imidazolidines as aldose reductase inhibitors and their pharmaceutical use

Also Published As

Publication number Publication date
JPH01503460A (ja) 1989-11-22
EP0306525A4 (en) 1991-04-24
AU1549088A (en) 1988-10-10
AU598366B2 (en) 1990-06-21
EP0306525A1 (fr) 1989-03-15
KR890700346A (ko) 1989-04-24
WO1988006887A1 (fr) 1988-09-22

Similar Documents

Publication Publication Date Title
Boden et al. Acute lowering of plasma fatty acids lowers basal insulin secretion in diabetic and nondiabetic subjects.
Petersen et al. Mechanism by which glucose and insulin inhibit net hepatic glycogenolysis in humans.
Wiethop et al. Alanine and terbutaline in treatment of hypoglycemia in IDDM
Jenkins et al. Exercise-induced hepatic glucose output is precisely sensitive to the rate of systemic glucose supply
KR20010020497A (ko) 당뇨병 치료 방법
US5430065A (en) Therapeutical method for enhancing peripheral glucose utilization in a non-insulin-dependent diabetic patient
Kobayashi et al. Pathogenic factors of glucose intolerance in obese Japanese adolescents with type 2 diabetes
EP0808164B1 (fr) Utilisation des modulateurs de prolactine et l'application d'un regimeprocede pour obtenir un medicament pour le traitement de l'obesite
JP2012006923A (ja) 糖尿病の治療及び予防のためのフタリド誘導体の使用
WO1993018761A1 (fr) Compositions pharaceutiques et procedes dans lesquels on utilise de l'isobutyramide pour traiter des dereglements de la beta-globine
JPH05507943A (ja) 糖尿病、低血糖および他の状態の治療のための方法および組成物
US20040142868A1 (en) Method of treating liver steatosis in a mammal
Schmitz et al. Glucose uptake and pulsatile insulin infusion: Euglycaemic clamp and [33H] glucose studies in healthy subjects
Lardinois et al. Glyburide in non-insulin-dependent diabetes: its therapeutic effect in patients with disease poorly controlled by insulin alone
CA2372948A1 (fr) Technique permettant d'ameliorer l'action de l'insuline
CA1310269C (fr) Utilisation d'inhibiteurs de la reductase de l'aldose pour accroitre la sensibilite a l'insuline dans le diabete sucre
Lardinois et al. Acarbose treatment of non-insulin-dependent diabetes mellitus
Romanelli et al. Short-term administration of captopril and nifedipine and exercise-induced albuminuria in normotensive diabetic patients with early-stage nephropathy
Iqbal et al. Thalidomide impairs insulin action on glucose uptake and glycogen synthesis in patients with type 2 diabetes.
Saurat et al. Arotinoid acid (Ro 13-7410): a pilot study in dermatology
HENDLER et al. Epinephrine-stimulated glucose production is not diminished by starvation: Evidence for an effect on gluconeogenesis
PT2724722T (pt) Método de restaurar o efeito incretina
Campbell The Somogyi phenomenon. A short review
Bailey et al. Enhancement of insulin release to acute glycaemic stimulation with depression of basal insulin production rates in insulinoma following diazoxide administration
Arslanian et al. Impaired insulin mediated potassium uptake in adolescents with IDDM

Legal Events

Date Code Title Description
MKLA Lapsed